RU1821211C - Hypolipidemic medicine - Google Patents

Abstract

The invention relates to medicine, namely to pharmacology. The goal is to create a drug that affects the blood levels of low lipoproteins (LP.NP) and very low density (VLDL). As such a remedy, hemodesis is used.

Description

The invention relates to medicine, namely to pharmacology.

The purpose of the invention is to provide an agent that affects the blood levels of low lipoproteins (VLDL) and very low density (VLDL).

The levels of low and very low density lipoproteins in serum taken from a blood vein and at an LDL value of 4.38 mmol / L (according to the method of D. B. Shestov) and VLDL 0.65 mmol / L are determined in a patient with coronary heart disease (IHD) according to the methodology of B. Rifkind, 1985), an intravenous droplet effect of the geodesis is carried out in an amount of 200 ml at a rate of 60 cap. in minutes 30 minutes, and 24 hours after the end of the administration of haemodesus, the LDL and VLDL levels were re-determined for control. 5-10 days after the first infusion of hemodez, the procedure is repeated. Re-infusion of hemedea is carried out even with good LDL and VLDL parameters in order to achieve the elimination effect of hemodesis not only from the bloodstream, but also from the tissues. A third hemodesis infusion can be carried out after another 5-10 days. In addition, patients with coronary heart disease

receive conventional complex antianginal therapy, including calcium nitrate antagonists, β-adrenergic blockers, etc. The daily dose and combination of drugs are selected individually. Examples of implementation of the proposal.

Example No. 1. Patient M., 45 years old. Diagnosis: IHD: angina pectoris, functional class II, coronary artery atherosclerosis, atherosclerotic cardiosclerosis, aortic atherosclerosis, extrasystoles. Upon admission to the hospital had the following indicators:

5.94 mmol / L 1.35 mmol / L 0.91 mmol / L 3.85 mmol / L

Total cholesterol Triglycerides VLDL LDL Circulating immune complex 40 units After the tests, 200 ml of intravenous intravenous drip was administered at a rate of 60 drops. in T min After 30 minutes, after infusion, the analysis was repeated:

Total cholesterol5.71 Triglycerides 1.01 VLDL 0.45

00

TO)

fo

LDL 3.51 Circulating immune complex 40 units. After 1 day

Total cholesterol5.61 Triglycerides 0.67 VLDLP 0.29 LDL 3.36 Circulating immunocomplex 35 units. From the first day after the injection of the hemodez, the patient received nitrong (2.6 mg 3 r per day), sydnopharm (0.002 x 3 r per day), repabolil (5% - 1 ml per mouse after 10 days), sedatives.

After 10 days, 200 ml of hemodesis was reintroduced. She felt better, heart pain decreased and became less frequent. The third infusion of haemodesis was carried out after another 10 days. The patient was treated in a hospital for 26 days. Before discharge, blood tests: XC5.44 TG 0.67 VLDLP 0.29 LDL 3.01 Circulating immunocomplex 30 units. The patient was discharged in satisfactory condition, there was no pain in the heart.

0

5

0

5

0

It is recommended to use a syndopharm in case of pain.

The proposed method treated more than 100 patients and received a positive result.

There is a rapid decrease in the levels of low and very low density lipoproteins in the blood and tissues.

Eliminates the need for prolonged use of the drug, because an already 2-3-fold infusion of hemorrhage reduces the levels of LDL and VLDL to normal, which eliminates the potential for the occurrence of immunological changes involved in the development of atherosclerosis.

The drug in the complex is excreted by the kidneys, this eliminates the possibility of getting used to it.

Haemodesis does not have undesirable side effects on the body, reduces the need for oxygen in the myocardium, which allows to reduce the daily dose of antiangionic drugs.

FORMULA AND SECTION

Use of haemodesis as a treatment for dyslipoproteinemia.